Skip to Main Content.
Human Subjects site of Office of Research Support link to UT home link to Office of Research Support

The Office of Research Support (ORS) does not administer or oversee HOP policy 5-2011 or training related to the policy. ORS administers HOP policy 7-1210, “Promoting Objectivity in Research by Managing, Reducing or Eliminating Financial Conflicts of Interest” so if you conduct research and have:

  1. Not submitted a Financial Interest Disclosure (FID), you will need to complete mandatory training and file a FID. Instructions for completing these requirements are located at http://www.utexas.edu/research/rsc/coi/training.html.
  2. Previously submitted a FID, you are not required to complete additional training nor re-disclose the same information to comply with the UTS 180/HOP 5-2011 policy requirements.   However, you may have other responsibilities under that policy.

HOP policy 5-2011 QUESTIONS? Contact the Provost’s Office evpp_coi@austin.utexas.edu or call Mike Kerker, Associate Vice Provost at (512) 471-2694.

Financial Conflicts of Interest in PHS-funded Research

In accordance with PHS regulations, this web page provides public access to information pertaining to Financial Conflicts of Interest (FCOI) of PHS-funded research. The information on this web page will remain available for three (3) years after its most recent update. Information required by PHS regulation:

  1. the covered individual’s name;
  2. the covered individual’s title and role with respect to the research;
  3. the name of the entity in which the financial interest is held;
  4. the nature of the financial interest that constitutes a financial conflict of interest; and
  5. the approximate value of the financial interest by range or, if the dollar value cannot be determined by reference to public prices or other reasonable measures of fair market value, a statement to that effect.

A management plan is established in cooperation with the Covered Individual to address the FCOI per University policy. The information posted on this website is derived from the management plan.

The FCOI posted on this website is current as of October 20, 2014 and is subject to updates, on at least an annual basis and within 60 days of the University’s identification of the FCOI.

Alan Lambowitz, Ph.D.
Posted: September 19, 2014

Title and Role with Respect to the Research
Director, Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
InGex, LLC.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual and a Covered Family Member hold equity interest in InGex, LLC. The Covered Individual conducts research on intellectual property involving targetron technology and group II intron reverse transcriptases that is licensed by the University to InGex, LLC for commercialization.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
31-45 % equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Hugh Smyth, Ph.D.
Posted: September 19, 2014

Title and Role with Respect to the Research
Associate Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Respira Therapeutics, Inc.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is a Consulting Chief Scientist to Respira Therapeutics, Inc. and an inventor of technologies used by Respira Therapeutics, Inc. The Covered Individual receives reimbursement for travel relating to consulting for Respira Therapeutics, Inc. The business interests of Respira Therapeutics, Inc. overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
$10,000-$19,999

Ning Jiang, Ph.D.
Posted: September 19, 2014

Title and Role with Respect to the Research
Assistant Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
“Measurement and Comparison of Immune Diversity by High-throughput Sequencing.”

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is in an agreement to receive royalties from the licensing of intellectual property that overlaps with her area of research involving systems immunology.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Stanislav Emelianov, Ph.D.
Posted: December 4, 2013

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
NanoHybrids, LLC.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual and Covered Family Member are founding members and on the board of directors of NanoHybrids, LLC. The Covered Individual and Covered Family Member hold equity interest in NanoHybrids, LLC and the Covered Individual conducts research in areas of interest to NanoHybrids, LLC.

A NanoHybrids, LLC employee works in the Covered Individual’s University laboratory for Ultrasound Imaging and Therapeutics Research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
12-24% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Everett Stone, Ph.D.
Posted: September 19, 2014

Title and Role with Respect to the Research
Research Scientist and Principal Investigator

Name of Entity in which the Financial Interest is Held
GMA, LLC and Aeglea, LLC

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual holds equity interest in GMA, LLC and Aeglea, LLC. The Covered Individual conducts sponsored research on intellectual property that has been assigned to GMA, LLC. Aeglea, LLC develops protein drugs related to the technology owned by GMA, LLC. The Covered Individual is a consultant for engineering, development, and manufacture of therapeutic proteins for Aeglea, LLC. The business interests of GMA, LLC and Aeglea, LLC overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
6-10% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. (GMA, LLC).

5% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. (Aeglea, LLC).

Kenneth Diller, Ph.D.
Posted: December 9, 2013

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Bioheat Transfer, LLC and Cool Core Biomedical Technologies, LLC

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is the President of Bioheat Transfer, LLC and the Chief Scientific Officer of Cool Core Biomedical Technologies, LLC. The Covered Individual holds equity interest in Bioheat Transfer, LLC and Cool Core Biomedical Technologies, LLC. The Covered Individual conducts research in areas of interest to Bioheat Transfer, LLC and Cool Core Biomedical Technologies, LLC

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
75% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. (Bioheat Transfer, LLC)
45% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.(Cool Core Biomedical Technologies, LLC)

Konstantin Sokolov, Ph.D.
Posted: January 14, 2014

Title and Role with Respect to the Research
Adjunct Associate Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
NanoHybrids, LLC.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is a founding member and on the board of directors of NanoHybrids, LLC. The Covered Individual holds equity interest in NanoHybrids, LLC and conducts research in areas of interest to NanoHybrids, LLC.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
11-20% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Sepideh Khoshnevis, MD
Posted: February 14, 2014

Title and Role with Respect to the Research
Graduate Research Assistant

Name of Entity in which the Financial Interest is Held
Bioheat Transfer, LLC

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual holds equity interest in Bioheat Transfer, LLC. The business interests of Bioheat Transfer, LLC overlap with the Covered Individual’s research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
22% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Miyong Kim, Ph.D.
Posted: September 19, 2014

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Korean Resource Center

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual’s covered family member is a paid officer at the Korean Resource Center. The Korean Resource Center is involved in research of which the Covered Individual is Principal Investigator and primary grantee of federal funding. Grant funds that support the Covered Individual’s research are subawarded to the Korean Resource Center.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
$100,000 – 150,000

George Georgiou, Ph.D.
Posted: September 19, 2014

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
GMA, LLC and Aeglea, LLC

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual holds equity interest in GMA, LLC. The Covered Individual conducts sponsored research on intellectual property that has been assigned to GMA, LLC. The Covered Individual is co-founder, a member of the board of directors, and holds equity interest in Aeglea, LLC.The Covered Individual is inventor of technology licensed to Aeglea, LLC through GMA, LLC. The Covered Individual receives research funding from Aeglea, LLC. The business interests of GMA, LLC and Aeglea, LLC overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
51-100% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value (GMA, LLC)

11-20% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value (Aeglea, LLC)

Richard Finnell, Ph.D.
Posted: April 14, 2014

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
TeratOmic Consulting, LLC.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is CEO of TeratOmic Consulting, LLC, a company that provides expert opinion for legal matters related to toxic compounds that cause birth defects. The business interests of TeratOmic Consulting, LLC overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
$80,000 – $99,999

Robert Matthew Brothers, Ph.D.
Posted: September 19, 2014

Title and Role with Respect to the Research
Assistant Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Bioheat Transfer, LLC

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual holds equity interest in Bioheat Transfer, LLC. The business interests of Bioheat Transfer, LLC overlap with the Covered Individual’s research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
3% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Scott Hunicke-Smith, Ph.D.
Posted: September 19, 2014

Title and Role with Respect to the Research Director and Collaborator

Name of Entity in which the Financial Interest is Held Bioo Scientific Corporation

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest: The Covered Individual is a member of the Board of Directors and holds equity interest in Bioo Scientific Corporation. The business interests of Bioo Scientific Corporation overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect 0-5% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.